CWI1-2

Research use only, not for human use.

CWI1-2 is a potent IGF2BP2 inhibitor that inhibits its interaction with M6A-modified target transcripts by binding IGF2BP2. CWI1-2 has anti-leukemic activity and can induce apoptosis and differentiation.

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

Apoptosis AnalysisCell Line:MonoMac6, MOLM13Concentration:0-1 μM Incubation Time:24 h Result:Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells. Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells. Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.

——

——

Apoptosis

Apoptosis

Apoptosis

——

——

2408590-36-1

519.77

C22H17Cl3N6O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (192.39 mM; Ultrasonic )

ClC1=CC=C(O)C(C=NN=C(NN=CC2=CC(Cl)=CC=C2O)NN=CC3=CC(Cl)=CC=C3O)=C1

——

(-20℃)

With Ice Pack

≥ 2 years